

Abstract of the Disclosure

[00133] The present invention relates to methods of treating neurodegenerative diseases or disorders, such as Parkinson disease and related cognitive diseases or disorders with compounds and compositions of compounds having D4 and/or 5-HT_{2A} antagonistic, partial agonistic or inverse agonistic activity in combination with other compounds for treating said diseases. The invention also relates to pharmaceutical compositions for administration to a patient diagnosed as having a neurodegenerative disease or disorder and/or a cognitive disease or disorder, said pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compounds having 5-HT_{2A} antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound or compositions of said compounds in combination with another compound for treating said diseases or disorders to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said other compound.